Scarica l'app Stockscreener
69.97
8.72%
5.61
Precedente Chiudi:
$64.36
Aprire:
$71.5
Volume 24 ore:
99,258
Relative Volume:
2.58
Capitalizzazione di mercato:
$96.00M
Reddito:
$697.00K
Utile/perdita netta:
$-38.97M
Rapporto P/E:
-2.4065
EPS:
-29.075
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
+19.10%
1M Prestazione:
+19.14%
6M Prestazione:
+802.84%
1 anno Prestazione:
-90.34%
Intervallo 1D:
$65.34
$80.00
Intervallo di 1 settimana:
$55.89
$80.00
Portata 52W:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Nome
Spruce Biosciences Inc
Settore
Industria
Telefono
(415) 655-4168
Indirizzo
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
69.97 | 88.30M | 697.00K | -38.97M | -33.33M | -29.07 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-03-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Iniziato | Guggenheim | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-11-03 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
Spruce Stock Ignites: A 24% Surge Defies Gravity as Energy Winds Shift - Bitget
Citizens reiterates Spruce Biosciences stock rating on approval outlook - Investing.com
Spruce Biosciences Reports 2025 Financial Results, Advances TA-ERT Toward FDA Approval for MPS IIIB and Secures $50M Growth Capital - Minichart
Spruce Biosciences to end collaboration agreement with Kaken Pharmaceutical - Investing.com
Spruce Biosciences On March 16, Entered Termination Agreement With Kaken PharmaceuticalSEC Filing - TradingView
Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline - TipRanks
Spruce Biosciences, Inc. announced that all license agreements and corresponding rights previously signed with Kaken Pharmaceutical Co., Ltd. will be terminated. - Bitget
Spruce Biosciences (Nasdaq: SPRB) cuts 2025 loss, exits Kaken pact to focus TA-ERT - Stock Titan
Spruce Biosciences (SPRB) appoints Dale Hooks as CCO and reports narrowed $39M 2025 net loss - MSN
Does Spruce Biosciences (SPRB) have the potential to rally 208.32% as Wall Street analysts expect? - MSN
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect? - Zacks Investment Research
Is There a Chance for Spruce Biosciences (SPRB) to Surge by 208.32% According to Wall Street Analysts? - Bitget
Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss - Insider Monkey
Spruce Biosciences names Dale Hooks as chief commercial officer - Investing.com Nigeria
HC Wainwright Issues Optimistic Outlook for SPRB Earnings - MarketBeat
Oppenheimer Remains a Buy on Spruce Biosciences (SPRB) - The Globe and Mail
SPRB: Citizens Lowers Price Target but Maintains Market Outperfo - GuruFocus
SPRB: Lead therapy for MPS IIIB advances toward Q4 BLA submission with strong clinical and regulatory momentum - TradingView
Spruce Biosciences (NASDAQ:SPRB) Announces Quarterly Earnings Results - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Given New $170.00 Price Target at Citizens Jmp - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Earns "Buy" Rating from HC Wainwright - MarketBeat
SPRB: HC Wainwright & Co. Reiterates Buy Rating with $200 PT | S - GuruFocus
Spruce Biosciences names Dale Hooks as chief commercial officer By Investing.com - Investing.com Canada
[Form 4] SPRUCE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Spruce Biosciences (SPRB) Chief Commercial Officer files Form 3 - Stock Titan
Spruce Biosciences Reports 2025 Financial Results, Advances TA-ERT for MPS IIIB with FDA, and Secures $50M Growth Capital - Minichart
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Com - PharmiWeb.com
Spruce Biosciences, Inc. 2024 Annual Report: Business Overview, Risk Factors, Pipeline, and Regulatory Updates - Minichart
SPRB: TA-ERT program progresses toward BLA submission as net loss narrows and cash runway extends - TradingView
SPRB: TA-ERT is BLA-ready for MPS IIIB, with durable efficacy, safety, and strong market potential - TradingView
Spruce Biosciences Appoints Dale Hooks as Chief Commercial Officer - Contract Pharma
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates - pharmiweb.com
According to the latest documents submitted to the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Spruce Biosciences, Inc. has been authorized to offer and sell its common stock under the current sales agreement, with the tota - Bitget
Spruce Biosciences Updates ATM Agreement, Strengthens Leadership Team - TipRanks
Spruce Biosciences 10-K: $0.0M Revenue, $(50.83) EPS on $(39.0)M Net Loss - TradingView
Spruce Biosciences Launches New ATM Equity Program With Jefferies - TradingView
Spruce Biosciences (NASDAQ: SPRB) launches $75M ATM program with Jefferies - Stock Titan
Spruce Biosciences, Inc. recently announced the official appointment of Dale Hooks, who has outstanding achievements in the commercialization of rare diseases, as the company's Chief Commercial Officer. - Bitget
Spruce Biosciences Reports Full Year 2025 Financial Results - TradingView
Spruce Biosciences (NASDAQ: SPRB) trims 2025 loss, adds growth capital - Stock Titan
Spruce Biosciences 2025 net loss narrows, secures $50 mln funding - TradingView
Rare disease drug TA-ERT heads for 2026 FDA filing after key data - Stock Titan
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer - Bluefield Daily Telegraph
Spruce Biosciences Stock More Than Quadruples After Breakthrough Therapy Designation To Therapy For Rare And Fatal Genetic Disease - MSN
Spruce Biosciences reports positive FDA meetings as it prepares TA-ERT filing for rare pediatric disorder - MSN
Spruce Biosciences (SPRB) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway - Yahoo Finance
12 Most Promising Micro-Cap Stocks According to Analysts - Insider Monkey
SPRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Spruce Biosciences Inc Azioni (SPRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):